scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1039806518 |
P356 | DOI | 10.1186/AR4503 |
P932 | PMC publication ID | 4060229 |
P698 | PubMed publication ID | 24612997 |
P5875 | ResearchGate publication ID | 260681858 |
P50 | author | Gabriela Riemekasten | Q21260007 |
Gerd-Rüdiger Burmester | Q47261275 | ||
P2093 | author name string | Duska Dragun | |
Harald Heidecke | |||
Mislav Radić | |||
Jeannine Günther | |||
Elise Siegert | |||
Angela Kill | |||
Mike Oliver Becker | |||
Judith Rademacher | |||
P2860 | cites work | Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes | Q24647107 |
Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines | Q28564355 | ||
Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes | Q32072042 | ||
Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway | Q33903180 | ||
Teaching old receptors new tricks: biasing seven-transmembrane receptors | Q33985759 | ||
The multiple actions of angiotensin II in atherosclerosis | Q34060768 | ||
Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor | Q34099697 | ||
Essential role of Smad3 in angiotensin II-induced vascular fibrosis | Q34575283 | ||
Central role of the AT(1)-receptor in atherosclerosis | Q34761161 | ||
Role of the renin-angiotensin system in vascular inflammation | Q34789029 | ||
Inflammation and angiotensin II. | Q35099157 | ||
Endothelin and endothelin receptor antagonists in systemic rheumatic disease | Q35127435 | ||
Systemic sclerosis: a prototypic multisystem fibrotic disorder | Q35649427 | ||
Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling | Q35681804 | ||
Sequential dermal microvascular and perivascular changes in the development of scleroderma | Q68034596 | ||
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis | Q68330753 | ||
In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease | Q71607968 | ||
Angiotensin II receptor subtypes AT1 and AT2 are down-regulated by angiotensin II through AT1 receptor by different mechanisms | Q72996198 | ||
AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage | Q74188173 | ||
Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts | Q74573150 | ||
Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors | Q75288461 | ||
CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis | Q80238474 | ||
Autoantibodies against G-protein-coupled receptors modulate heart mast cells | Q80278334 | ||
Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines | Q81072711 | ||
Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis | Q81162536 | ||
Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 | ||
Reduced expression of angiotensin II and angiotensin receptor type 1 and type 2 in resistance arteries from nasal lesions in granulomatosis with polyangiitis (Wegener's granulomatosis) | Q84971305 | ||
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease | Q35763490 | ||
Is systemic sclerosis an antigen-driven T cell disease? | Q35799608 | ||
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database | Q35953368 | ||
Is preeclampsia an autoimmune disease? | Q36050775 | ||
Vascular endothelin in hypertension | Q36162950 | ||
Scleroderma: from cell and molecular mechanisms to disease models | Q36259889 | ||
Inflammation in hypertension. | Q36398035 | ||
Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein | Q36470843 | ||
Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. | Q36591603 | ||
Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis | Q36667816 | ||
Genetic factors in systemic sclerosis | Q36927757 | ||
Molecular pathways as novel therapeutic targets in systemic sclerosis | Q36961452 | ||
Regulation of T-cell function by endogenously produced angiotensin II. | Q37100479 | ||
Expression and function of ETA and ETB receptors in SSc. | Q37265814 | ||
Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients | Q37350899 | ||
Non-invasive biomarkers in pulmonary fibrosis | Q37585596 | ||
Cellular and molecular aspects of vascular dysfunction in systemic sclerosis | Q37768336 | ||
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee | Q39513167 | ||
A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. | Q40328974 | ||
Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. | Q42154997 | ||
CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity | Q42481241 | ||
AT1 receptor-mediated angiotensin II activation and chemotaxis of T lymphocytes | Q42489417 | ||
Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 | ||
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection | Q45259438 | ||
Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role? | Q45715684 | ||
Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 | ||
Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism | Q46481430 | ||
Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries | Q46618559 | ||
Angiotensin II type 1 receptor expression on human leukocyte subsets: a flow cytometric and RT-PCR study. | Q46986151 | ||
Evaluation of the effect of Bosentan treatment on proinflammatory cytokine serum levels in patients affected by Systemic Sclerosis | Q48513015 | ||
Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. | Q52886517 | ||
Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. | Q52900457 | ||
Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. | Q52940276 | ||
Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. | Q53568433 | ||
Preliminary criteria for the classification of systemic sclerosis (scleroderma) | Q54165663 | ||
Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis | Q58234794 | ||
P433 | issue | 2 | |
P921 | main subject | autoantibody | Q785022 |
P304 | page(s) | R65 | |
P577 | publication date | 2014-03-11 | |
P1433 | published in | Arthritis Research and Therapy | Q15757229 |
P1476 | title | Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients | |
P478 | volume | 16 |